If you have been reading about melanocortin receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-04. Numbers and descriptions here follow the published literature rather than marketing material.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Melanotan-2 appears on the World Anti-Doping Agency prohibited list within the peptide hormone class, and several national regulators treat it as an unapproved prescription substance. Some countries restrict importation or sale for personal use. Because the compound is widely traded as a research chemical, the practical legal picture differs between jurisdictions and shifts over time. Human safety data covering long periods are limited, and whether repeated pigmentation changes carry any lasting risk to melanocytes remains an open question.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
=== Effects on longevity === mTOR, specifically mTORC1, was first shown to be important in aging in 2003, in a study on worms; sirolimus was shown to inhibit and slow aging in worms, yeast, and flies, and then to improve the condition of mouse models of various diseases of aging. Sirolimus was first shown to extend lifespan in wild-type mice in a study published by NIH investigators in 2009; the studies have been replicated in mice of many different genetic backgrounds. A study published in 2020 found late-life sirolimus dosing schedules enhanced mouse lifespan in a sex-specific manner: limited rapamycin exposure enhanced male but not female lifespan, providing evidence for sex differences in sirolimus response. The results are further supported by the finding that genetically modified mice with impaired mTORC1 signalling live longer. Sirolimus has potential for widespread use as a longevity-promoting drug, with evidence pointing to its ability to prevent age-associated decline of cognitive and physical health. In 2014, researchers at Novartis showed that a related compound, everolimus, increased elderly patients' immune response on an intermittent dose. This led to many in the anti-aging community self-experimenting with the compound. However, because of the different biochemical properties of sirolimus, the dosing is potentially very different from that of everolimus.
In April 2026, Hegseth compared the press to biblical Pharisees. "The Pharisees: the so-called and self-appointed elites of their time, they were there to witness, to write everything down, to report," Hegseth said.
=== Patuxent Environmental & Aquatic Research Laboratory === The Morgan State University Patuxent Environmental & Aquatic Research Laboratory (PEARL) is located 80 miles south of the main campus on the shoreline of the Patuxent River - a major tributary of the Chesapeake Bay. PEARL research is designed to increase the understanding of coastal and environmental systems so that they can be properly managed and protected. PEARL is dedicated to solving complex environmental problems, applying interdisciplinary approaches to studying the connections between complex ecological systems, while providing society with knowledge to meet the environmental challenges of the 21st century.
Sources: en.wikipedia.org
A police investigation into claims former Conservative MP Mark Menzies misused donors' money to pay "bad people" is dropped after he agreed to repay the money. Former Conservative minister Maria Caulfield, who lost her seat at the last election, joins Reform UK. Mark McEwan steps down as Standards Commissioner at Stormont a week after his appointment to take up the post of Deputy Chief Constable of Surrey Police. 17 September – Mason Humberstone, a member of Stevenage Borough Council, becomes the first Labour Party councillor to defect to Reform UK. 18 September – The Newham Independents win a local by-election in Plaistow South. 19 September – The Terminally Ill Adults (End of Life) Bill passes its second reading in the House of Lords. Jamie Hepburn resigns as the Scottish Government's Minister for Cabinet and Parliamentary Business following a complaint that he assaulted former Conservative leader Douglas Ross as the two were leaving the Scottish Parliament building two days earlier. Wales's Health Minister, Jeremy Miles, announces he will not stand in the 2026 Senedd election. John Allen, a councillor on Northumberland County Council, is suspended from Reform UK following allegations he made online threats to kill the prime minister. A schism breaks out between Zarah Sultana and Jeremy Corbyn over Your Party. Andy Burnham says he "isn't ruling out" a return to Westminster politics. 20 September – The Liberal Democrat conference starts in Bournemouth. Gavin Robinson launches the Democratic Unionist Party conference in Belfast.
Car buyers must pay for Additional Registration Fees (ARF) duties of either 100%, 140%, 180% or 220% of the vehicle's Open Market Value (OMV), and bid for a Singaporean Certificate of Entitlement (COE) (that varies twice a month in supply based on the number of car registrations and de-registrations), which allows the car to be driven on the road for maximum period of 10 years. Car prices are generally significantly higher in Singapore than in other English-speaking countries. As with most Commonwealth countries, vehicles on the road and people walking on the streets keep to the left (left-hand traffic). In 2025, Singapore started actively engaging in autonomous vehicle testing. In November 2025, the Land Transport Authority (LTA) approved WeRide and Grab to test 11 autonomous vehicles on two Punggol shuttle routes after initial tests in October, and aim for public passengers by early 2026. The Johor–Singapore Causeway (connecting Singapore with Johor Bahru, Malaysia) is the busiest international land border crossing in the world, whereby approximately 350,000 travellers cross the border checkpoints of both Woodlands Checkpoint and Sultan Iskandar Building daily (with an annual total of 128 million travellers). The Land Transport Authority (LTA) is responsible for all land transport-related infrastructure and operations in Singapore.
A 2021 case report documented a 72‑year‑old woman with Lewy body dementia who developed fatal neuroleptic malignant syndrome (NMS) after receiving a single 156 mg intramuscular injection of paliperidone palmitate; she remained comatose and died following a prolonged hospital course after palliative care measures were initiated. The use of high‑dose, high‑potency, or long‑acting injectable formulations of antipsychotics increases the risk of developing NMS. Multiple additional case reports of NMS linked to paliperidone palmitate have been published, including a 63-year-old man (2025) who survived after treatment, and cases in a 29-year-old woman who developed severe, treatment‑refractory NMS after two doses of paliperidone palmitate (2025) and a 24-year-old man (2025).
==== Termination of Peter Rost (2005) ==== Peter Rost was vice president in charge of the endocrinology division at Pharmacia before its acquisition by Pfizer. During that time he raised concerns internally about kickbacks and off-label marketing of Genotropin, Pharmacia's human growth hormone drug. Pfizer reported the Pharmacia marketing practices to the FDA and Department of Justice; Rost was unaware of this and filed an FCA lawsuit against Pfizer. Pfizer kept him employed, but isolated him until the FCA suit was unsealed in 2005. The Justice Department declined to intervene, and Pfizer fired him, and he filed a wrongful termination suit against Pfizer. Pfizer won a summary dismissal of the case, with the court ruling that the evidence showed Pfizer had decided to fire Rost prior to learning of his whistleblower activities.
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
No. It is a laboratory-made peptide, while the natural hormone is alpha-melanocyte-stimulating hormone, a longer peptide produced by the pituitary gland and by skin cells. Melanotan-2 mimics only a short active region of that hormone and contains non-natural residues such as D-phenylalanine.